Click the play button below for an interview with Garrett Dilley at Informex

Company Profile

Founded in 1991, Albany Molecular Research, Inc. (Nasdaq: AMRI) is a leading chemistry-based drug discovery and development company, focusing on applications for new small molecule prescription drugs. The company conducts R&D projects and collaborates with many leading pharmaceutical, biotechnology and genomics companies, and is developing new chemistry technology for potential pharmaceutical products. AMRI generates fee-for-service revenue from its strong and profitable contracts and collaborative relationships with leading pharma and biotech companies, and receives royalties on technology it has developed and outlicensed.

Albany Molecular Research has expertise in comprehensive chemistry applications required in small molecule drug discovery and development, from the earliest stages of lead generation and optimization through chemical process development and cGMP synthesis. A key strategy is to develop or acquire promising new technology to strengthen the ability to provide added value to difficult small molecule projects. Company research has led to dozens of existing and pending patents, including important patents for the active ingredient in the non-sedating antihistamine, Allegra,TM developed and marketed by Aventis.

Business Strategy

In the near term, Albany Molecular Research is expanding and strengthening its chemistry services platform, to work on more projects for more collaborators throughout the world. Longer term, through its investment in cutting edge discovery and development technologies and its investment in early stage research projects for new small molecule prescription drug candidates, AMRI is seeking to enhance the value it can bring to its collaborators and participate in the success of a drug candidate through the receipt of milestone and royalty payments, ultimately increasing the value it can create for its shareholders.

Key Competitive Strengths

Highest standards for scientific research excellence, ethics, work ethic and customer service

Experienced management team with pharmaceutical industry record of accomplishment

Proprietary combinatorial biocatalysis technology platform for generating improved drug leads

Strength in medicinal chemistry lead optimization, chemical development research and analytical chemistry

Natural products and chemical sample screening libraries for unprecedented screening diversity, along with follow-on chemistry support

Strong capabilities in the biosciences, including fermentation, traditional biocatalysis and molecular biology

Cutting-edge technologies in computer-assisted drug design and combinatorial chemistry

Minority investment in Organichem Corporation provides cGMP pilot plant and larger scale cGMP chemical manufacturing